Kiadis Pharma pro­pos­es for­mer Actelion COO Otto Schwarz as new Supervisory Board mem­ber

Amsterdam-Duivendrecht, The Netherlands, July 26, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clin­i­cal stage bio­phar­ma­ceu­ti­cal com­pa­ny devel­op­ing inno­v­a­tive prod­ucts to make bone mar­row trans­plan­ta­tions safer and more effec­tive for patients suf­fer­ing from blood can­cers and inher­it­ed blood dis­or­ders, today announces that at its next General Meeting of Shareholders, the Kiadis Pharma Supervisory Board will nom­i­nate Dr. Otto Schwarz to be appoint­ed as a new mem­ber of the Supervisory Board.
Dr. Otto Schwarz is a high­ly accom­plished indus­try vet­er­an, with sig­nif­i­cant oper­a­tional and com­mer­cial lead­er­ship expe­ri­ence, includ­ing glob­al launch­es of mul­ti­ple major orphan and spe­cial­ty care prod­ucts. Most recent­ly, Otto was Executive Vice-President, Chief Operating Officer and a mem­ber of the Actelion Executive Committee, up to the recent acqui­si­tion of Actelion by Johnson & Johnson. At Actelion, which he joined in 2008, Otto was respon­si­ble for glob­al oper­a­tions includ­ing mar­ket­ing strat­e­gy & sales, med­ical affairs, man­u­fac­tur­ing and sup­ply chain, lead­ing over 1300 peo­ple. Under Otto’s lead­er­ship, Actelion suc­cess­ful­ly launched the orphan prod­ucts Opsumit, Uptravi and Veletri, grow­ing total com­pa­ny sales to well over €2 bil­lion. Prior to join­ing Actelion, he was Executive Vice-President Commercial Operations at Nycomed and an Executive Board Member at Altana Pharma. Prior to that he worked for almost 20 years at Schering-Plough and Eli Lilly in Austria, Switzerland, Canada, the US and Germany. Otto Schwarz is an Austrian cit­i­zen with a PhD in phar­ma­ceu­ti­cal chem­istry from Vienna University.
Arthur Lahr, CEO of Kiadis Pharma, com­ment­ed: “I am very pleased Otto has decid­ed to join our Supervisory Board. As we pre­pare for the poten­tial European com­mer­cial launch of ATIR101™ in 2019. Otto’s wealth of expe­ri­ence in launch­ing and grow­ing orphan and spe­cial­ty care prod­ucts, and in build­ing a strong, ful­ly inte­grat­ed biotech com­pa­ny, will be incred­i­bly valu­able for Kiadis Pharma. With Otto’s sup­port, we should be well posi­tioned to make ATIR101™ wide­ly avail­able to patients and a com­mer­cial suc­cess.’’
Otto Schwarz added: “I am very hap­py to join the Kiadis Pharma Supervisory Board and am impressed by the Company’s inves­ti­ga­tion­al prod­ucts and tech­nol­o­gy. I am com­mit­ted to bring my 30 years of expe­ri­ence to sup­port the fur­ther matur­ing of Kiadis Pharma as it enters the next impor­tant phas­es in its devel­op­ment, to help patients have safer and more effec­tive bone mar­row trans­plan­ta­tions.’’
Mark Wegter, Chairman of the Supervisory Board of Kiadis Pharma, com­ment­ed: “We are delight­ed to wel­come Otto to our Supervisory Board. He is well respect­ed with very rel­e­vant expe­ri­ence that will be invalu­able in the next stage of our evo­lu­tion, and he will help dri­ve the com­mer­cial strat­e­gy for our prod­ucts and con­tin­ued trans­for­ma­tion of the Company and our Board.

Leave a Reply

Your email address will not be published. Required fields are marked *